Détail - canceropole-wordpress

Cancer cell-derived IL-1β reverses chemo-immunotherapy resistance in non-small cell lung cancer.

Perrichet A, Lecuelle J, Limagne E, Thiefin M, Bellio H, Jacob P, Aucagne R, Aznague A, Russo P, Gaucher F, Roussot N, Yang X, Vernet T, Nuttin L, Ilie A, Rageot D, Derangère V, Huppe T, Zippelius A, Routy B, Truntzer C, Chalmin F, Ghiringhelli F, Rébé C

Nat Commun. 2025 11 21;16(1):10244

Tumor-Associated Macrophages Produce PGE2 to Promote CD8+ T Cell Exhaustion and Drive Resistance to PD-L1 Blockade in Microsatellite Stable Colorectal Cancer.

Fumet JD, Latour C, Nuttin L, Derangère V, Ilie A, Russo P, Hampe L, Daumoine S, Thibaudin M, Truntzer C, Ghiringhelli F, Limagne E

Cancer Res. 2025 11 6;:

Co-targeting TGF-β and PD-L1 sensitizes triple-negative breast cancer to experimental immunogenic cisplatin-eribulin chemotherapy doublet.

Kalfeist L, Ledys F, Petit S, Poirrier C, Kada Mohammed S, Galland L, Derangère V, Ilie A, Rageot D, Aucagne R, Bellaye PS, Truntzer C, Thibaudin M, Rialland M, Ghiringhelli F, Limagne E, Ladoire S

J Clin Invest. 2025 07 1;135(13):

Deep learning uncovers histological patterns of YAP1/TEAD activity related to disease aggressiveness in cancer patients.

Schmauch B, Cabeli V, Domingues OD, Le Douget JE, Hardy A, Belbahri R, Maussion C, Romagnoni A, Eckstein M, Fuchs F, Swalduz A, Lantuejoul S, Crochet H, Ghiringhelli F, Derangere V, Truntzer C, Pass H, Moreira AL, Chiriboga L, Zheng Y, Ozawa M, Howitt BE, Gevaert O, Girard N, Rexhepaj E, Valtingojer I, Debussche L, de Rinaldis E, Nestle F, Spanakis E, Fantin VR, Durand EY, Classe M, Von Loga K, Pronier E, Cesaroni M

iScience. 2025 01 17;28(1):111638

Safety and efficacy of trifluridine/tipiracil +/- bevacizumab plus XB2001 (anti-IL-1α antibody): a single-center phase 1 trial.

Thibaudin M, Roussot N, Burlot C, Schmitt A, Vincent J, Tharin Z, Bengrine L, Bellio H, Bertaut A, Hampe L, Daumoine S, Rederstorff E, Peroz M, Huppe T, Derangère V, Rageot D, Simard J, Truntzer C, Fumet JD, Ghiringhelli F

Signal Transduct Target Ther. 2025 01 17;10(1):22

Factors Influencing the Duration of Maintenance Therapy in Metastatic Colorectal Cancer.

Fourrier T, Truntzer C, Peroz M, Derangère V, Vincent J, Bengrine-Lefèvre L, Hennequin A, Palmier R, Orry D, Rabel T, Ghiringhelli F

Cancers (Basel). 2024 12 30;17(1):

Deep Multiple Instance Learning Model to Predict Outcome of Pancreatic Cancer Following Surgery.

Truntzer C, Ouahbi D, Huppé T, Rageot D, Ilie A, Molimard C, Beltjens F, Bergeron A, Vienot A, Borg C, Monnien F, Bibeau F, Derangère V, Ghiringhelli F

Biomedicines. 2024 12 2;12(12):

The DAV132 colon-targeted adsorbent does not interfere with plasma concentrations of antibiotics but prevents antibiotic-related dysbiosis: a randomized phase I trial in healthy volunteers.

Messaoudene M, Ferreira S, Saint-Lu N, Ponce M, Truntzer C, Boidot R, Le Bescop C, Loppinet T, Corbel T, Féger C, Bertrand K, Elkrief A, Isaksen M, Vitry F, Sablier-Gallis F, Andremont A, Bod L, Ghiringhelli F, de Gunzburg J, Routy B

Nat Commun. 2024 09 15;15(1):8083

Clinical Interest in Exome-Based Analysis of Somatic Mutational Signatures for Non-Small Cell Lung Cancer.

Peroz M, Mananet H, Roussot N, Kaderbhai CG, Derangère V, Truntzer C, Ghiringhelli F

Cancers (Basel). 2024 09 9;16(17):

Real-world prevalence, treatment and survival of "high risk" early breast cancer, with mandatory testing of gBRCA1/2 mutation according to the OlympiA trial inclusion criteria: Data from a population-based registry.

Ladoire S, Mamguem Kamga A, Galland L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie SM, Hennequin A, Jankowski C, Albuisson J, Nambot S, Coutant C, Arnould L, Reda M, Truntzer C, Dabakuyo S

Breast. 2024 08 28;78:103789

Case report: Immune response characterization of a pseudoprogression in a PD-L1-negative, TMB-low, co-mutated metastatic NSCLC.

Roussot N, Thibaudin M, Fumet JD, Daumoine S, Hampe L, Rébé C, Limagne E, Lagrange A, Herreros V, Lecuelle J, Mananet H, Ilie A, Rageot D, Boidot R, Goussot V, Comte A, Jacob P, Beltjens F, Bergeron A, Charon-Barra C, Arnould L, Derangère V, Ladoire S, Truntzer C, Ghiringhelli F

Front Immunol. 2024 08 7;15:1437961

Machine learning evaluation of immune infiltrate through digital tumour score allows prediction of survival outcome in a pooled analysis of three international stage III colon cancer cohorts.

Lecuelle J, Truntzer C, Basile D, Laghi L, Greco L, Ilie A, Rageot D, Emile JF, Bibeau F, Taïeb J, Derangere V, Lepage C, Ghiringhelli F

EBioMedicine. 2024 06 15;105:105207

Interleukin-1α as a Potential Prognostic Biomarker in Pancreatic Cancer.

Gigante L, Gaudillière-Le Dain G, Bertaut A, Truntzer C, Ghiringhelli F

Biomedicines. 2024 05 30;12(6):

Effect of radiochemotherapy on peripheral immune response in glioblastoma.

Hampe L, Daumoine S, Limagne E, Roussot N, Borsotti F, Vincent J, Ilie S, Truntzer C, Ghiringhelli F, Thibaudin M

Cancer Immunol Immunother. 2024 05 16;73(7):133

CD3-CD8 immune score associated with a clinical score stratifies PDAC prognosis regardless of adjuvant or neoadjuvant chemotherapy.

Schoumacher C, Derangère V, Gaudillière-Le Dain G, Huppe T, Rageot D, Ilie A, Vienot A, Borg C, Monnien F, Bibeau F, Truntzer C, Ghiringhelli F,

Oncoimmunology. 2023 12 21;13(1):2294563

The bacterial species profiles of the lingual and salivary microbiota differ with basic tastes sensitivity in human.

Licandro H, Truntzer C, Fromentin S, Morabito C, Quinquis B, Pons N, Martin C, Blottière HM, Neyraud E

Sci Rep. 2023 11 20;13(1):20339

FGF/FGFR genomic amplification as a predictive biomarker for immune checkpoint blockade resistance: a short report.

Roussot N, Lecuelle J, Dalens L, Truntzer C, Ghiringhelli F

J Immunother Cancer. 2023 10;11(10):

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial.

Thibaudin M, Fumet JD, Chibaudel B, Bennouna J, Borg C, Martin-Babau J, Cohen R, Fonck M, Taieb J, Limagne E, Blanc J, Ballot E, Hampe L, Bon M, Daumoine S, Peroz M, Mananet H, Derangère V, Boidot R, Michaud HA, Laheurte C, Adotevi O, Bertaut A, Truntzer C, Ghiringhelli F

Nat Med. 2023 08 10;:

A microbiota-modulated checkpoint directs immunosuppressive intestinal T cells into cancers.

Fidelle M, Rauber C, Alves Costa Silva C, Tian AL, Lahmar I, de La Varende AM, Zhao L, Thelemaque C, Lebhar I, Messaoudene M, Pizzato E, Birebent R, Mbogning Fonkou MD, Zoppi S, Reni A, Dalban C, Leduc M, Ferrere G, Durand S, Ly P, Silvin A, Mulder K, Dutertre CA, Ginhoux F, Yonekura S, Roberti MP, Tidjani-Alou M, Terrisse S, Chen J, Kepp O, Schippers A, Wagner N, Suárez-Gosálvez J, Kobold S, Fahrner JE, Richard C, Bosq J, Lordello L, Vitali G, Galleron N, Quinquis B, Le Chatelier E, Blanchard L, Girard JP, Jarry A, Gervois N, Godefroy E, Labarrière N, Koschny R, Daillère R, Besse B, Truntzer C, Ghiringhelli F, Coatnoan N, Mhanna V, Klatzmann D, Drubay D, Albiges L, Thomas AM, Segata N, Danlos FX, Marabelle A, Routy B, Derosa L, Kroemer G, Zitvogel L

Science. 2023 06 9;380(6649):eabo2296

GTN Enhances Antitumor Effects of Doxorubicin in TNBC by Targeting the Immunosuppressive Activity of PMN-MDSC.

Mabrouk N, Racoeur C, Shan J, Massot A, Ghione S, Privat M, Dondaine L, Ballot E, Truntzer C, Boidot R, Hermetet F, Derangère V, Bruchard M, Végran F, Chouchane L, Ghiringhelli F, Bettaieb A, Paul C

Cancers (Basel). 2023 06 9;15(12):

Intracranial response of brain metastases in patients with HER2-amplified breast cancer treated with trastuzumab-deruxtecan after failure of tucatinib-based therapy.

Desmoulins I, Bellio H, Méjean N, Truntzer C, Ladoire S

Eur J Cancer. 2023 05 9;187:161-163

Exome-Based Genomic Markers Could Improve Prediction of Checkpoint Inhibitor Efficacy Independently of Tumor Type.

Dalens L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Mananet H, Derangère V, Truntzer C, Ghiringhelli F

Int J Mol Sci. 2023 04 20;24(8):

Peroxisomal defects in microglial cells induce a disease-associated microglial signature.

Raas Q, Tawbeh A, Tahri-Joutey M, Gondcaille C, Keime C, Kaiser R, Trompier D, Nasser B, Leoni V, Bellanger E, Boussand M, Hamon Y, Benani A, Di Cara F, Truntzer C, Cherkaoui-Malki M, Andreoletti P, Savary S

Front Mol Neurosci. 2023 04 17;16:1170313

Inflammasome-independent NLRP3 function enforces ATM activity in response to genotoxic stress.

Bodnar-Wachtel M, Huber AL, Gorry J, Hacot S, Burlet D, Gérossier L, Guey B, Goutagny N, Bartosch B, Ballot E, Lecuelle J, Truntzer C, Ghiringhelli F, Py BF, Couté Y, Ballesta A, Lantuejoul S, Hall J, Tissier A, Petrilli V

Life Sci Alliance. 2023 04;6(4):

Predictive Factors of Local Recurrence after Colorectal Cancer Liver Metastases Thermal Ablation.

Odet J, Pellegrinelli J, Varbedian O, Truntzer C, Midulla M, Ghiringhelli F, Orry D

J Imaging. 2023 03 10;9(3):

Clinical Utility of Genomic Tests Evaluating Homologous Recombination Repair Deficiency (HRD) for Treatment Decisions in Early and Metastatic Breast Cancer.

Galland L, Roussot N, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Reda M, Albuisson J, Arnould L, Boidot R, Truntzer C, Ghiringhelli F, Ladoire S

Cancers (Basel). 2023 02 18;15(4):

SALL4-related gene signature defines a specific stromal subset of pancreatic ductal adenocarcinoma with poor prognostic features.

Vienot A, Monnien F, Truntzer C, Mougey V, Bouard A, Pallandre JR, Molimard C, Loyon R, Asgarov K, Averous G, Ghiringhelli F, Bibeau F, Peixoto P, Borg C

Mol Oncol. 2023 01 1;:

Integrative Clinical and DNA Methylation Analyses in a Population-Based Cohort Identifies and as Risk Recurrence Factors in Stage II Colon Cancer.

Tournier B, Aucagne R, Truntzer C, Fournier C, Ghiringhelli F, Chapusot C, Martin L, Bouvier AM, Manfredi S, Jooste V, Callanan MB, Lepage C

Cancers (Basel). 2022 12 27;15(1):

Efficacy of Chemotherapy Plus Bevacizumab in Recurrent Glioblastoma Multiform: A Real-life Study.

Beige A, Ghiringhelli F, Lecuelle J, Truntzer C, Truc G, Vincent J, Farah W, Borsotti F, Mazilu I, Ilie SM

Anticancer Res. 2022 12;42(12):5847-5858

Molecular intrinsic subtypes, genomic, and immune landscapes of BRCA-proficient but HRD-high ER-positive/HER2-negative early breast cancers.

Ballot E, Galland L, Mananet H, Boidot R, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

Breast Cancer Res. 2022 11 18;24(1):80

Weakly Supervised Learning using Attention gates for colon cancer histopathological image segmentation.

Ben Hamida A, Devanne M, Weber J, Truntzer C, Derangère V, Ghiringhelli F, Forestier G, Wemmert C

Artif Intell Med. 2022 11;133:102407

Critical analysis of the effect of various methodologies to compute breast cancer tumour blood flow-based texture features using first-pass F-FDG PET.

Payan N, Presles B, Truntzer C, Courcet E, Coutant C, Desmoulins I, Brunotte F, Vrigneaud JM, Cochet A

Phys Med. 2022 10 16;103:98-107

Downregulation of Elovl5 promotes breast cancer metastasis through a lipid-droplet accumulation-mediated induction of TGF-β receptors.

Kieu TL, Pierre L, Derangère V, Perrey S, Truntzer C, Jalil A, Causse S, Groetz E, Dumont A, Guyard L, Arnould L, de Barros JP, Apetoh L, Rébé C, Limagne E, Jourdan T, Demizieux L, Masson D, Thomas C, Ghiringhelli F, Rialland M

Cell Death Dis. 2022 09 2;13(9):758

Interplay between plasmacytoid dendritic cells and tumor-specific T cells in peripheral blood influences long-term survival in non-small cell lung carcinoma.

Laheurte C, Seffar E, Gravelin E, Lecuelle J, Renaudin A, Boullerot L, Malfroy M, Marguier A, Lecoester B, Gaugler B, Saas P, Truntzer C, Ghiringhelli F, Adotevi O

Cancer Immunol Immunother. 2022 08 21;:

Combination of CDX2 H-score quantitative analysis with CD3 AI-guided analysis identifies patients with a good prognosis only in stage III colon cancer.

Derangère V, Lecuelle J, Lepage C, Aoulad-Ben Salem O, Allatessem BM, Ilie A, Bouché O, Phelip JM, Baconnier M, Pezet D, Sebbagh V, Terrebonne E, Bouard G, Jooste V, Bouvier AM, Molimard C, Monnien F, Gonzalez D, Le Malicot K, Rageot D, Truntzer C, Bibeau F, Ghiringhelli F,

Eur J Cancer. 2022 07 1;172:221-230

Hematopoietic Prostaglandin D2 Synthase Controls Tfh/Th2 Communication and Limits Tfh Antitumor Effects.

Mary R, Chalmin F, Accogli T, Bruchard M, Hibos C, Melin J, Truntzer C, Limagne E, Derangère V, Thibaudin M, Humblin E, Boidot R, Chevrier S, Arnould L, Richard C, Klopfenstein Q, Bernard A, Urade Y, Harker JA, Apetoh L, Ghiringhelli F, Végran F

Cancer Immunol Res. 2022 05 25;:OF1-OF17

Custom multi‑tumor next‑generation sequencing panel for routine molecular diagnosis of solid tumors: Validation and results from three‑year clinical use.

Chevrier S, Brasselet A, Carnet M, Chevriaux A, Gibeaud A, Jourdain M, Mananet H, Truntzer C, Beltjens F, Charon-Barra C, Arnould L, Albuisson J, Comte A, Derangère V, Goussot V, Boidot R

Int J Mol Med. 2022 May;49(5):

Protein Kinase Inhibitor-Mediated Immunoprophylactic and Immunotherapeutic Control of Colon Cancer.

Ghione S, Racoeur C, Mabrouk N, Shan J, Groetz E, Ballot E, Truntzer C, Chouchane L, Végran F, Paul C, Plenchette S, Bettaieb A

Front Immunol. 2022 04 28;13:875764

Targeting PD-L1 and TIGIT could restore intratumoral CD8 T cell function in human colorectal cancer.

Thibaudin M, Limagne E, Hampe L, Ballot E, Truntzer C, Ghiringhelli F

Cancer Immunol Immunother. 2022 Mar 16;:

Efficacy of platinum-based chemotherapy in metastatic breast cancer and HRD biomarkers: utility of exome sequencing.

Galland L, Ballot E, Mananet H, Boidot R, Lecuelle J, Albuisson J, Arnould L, Desmoulins I, Mayeur D, Kaderbhai C, Ilie S, Hennequin A, Bergeron A, Derangère V, Ghiringhelli F, Truntzer C, Ladoire S

NPJ Breast Cancer. 2022 Mar 4;8(1):28

MER4 endogenous retrovirus correlated with better efficacy of anti-PD1/PD-L1 therapy in non-small cell lung cancer.

Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Boidot R, Chevrier S, Joubert P, Routy B, Truntzer C, Ghiringhelli F

J Immunother Cancer. 2022 Mar;10(3):

Genomic Instability Is Defined by Specific Tumor Microenvironment in Ovarian Cancer: A Subgroup Analysis of AGO OVAR 12 Trial.

Fumet JD, Lardenois E, Ray-Coquard I, Harter P, Joly F, Canzler U, Truntzer C, Tredan O, Liebrich C, Lortholary A, Pissaloux D, Leary A, Pfisterer J, Eeckhoutte A, Hilpert F, Fabbro M, Caux C, Alexandre J, Houlier A, Sehouli J, Sohier E, Kimmig R, Dubois B, Spaeth D, Treilleux I, Frenel JS, Herwig U, Le Saux O, Bendriss-Vermare N, du Bois A

Cancers (Basel). 2022 Feb 25;14(5):

Parallel evolution and differences in seroprevalence of SARS-CoV-2 antibody between patients with cancer and health care workers in a tertiary cancer centre during the first and second wave of COVID-19 pandemic: canSEROcov-II cross-sectional study.

Ladoire S, Rederstorff E, Goussot V, Parnalland S, Briot N, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2022 Feb 1;165:13-24

Recruitment and activation of type 3 innate lymphoid cells promote antitumor immune responses.

Bruchard M, Geindreau M, Perrichet A, Truntzer C, Ballot E, Boidot R, Racoeur C, Barsac E, Chalmin F, Hibos C, Baranek T, Paget C, Ryffel B, Rébé C, Paul C, Végran F, Ghiringhelli F

Nat Immunol. 2022 Feb;23(2):262-274

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.

Limagne E, Nuttin L, Thibaudin M, Jacquin E, Aucagne R, Bon M, Revy S, Barnestein R, Ballot E, Truntzer C, Derangère V, Fumet JD, Latour C, Rébé C, Bellaye PS, Kaderbhaï CG, Spill A, Collin B, Callanan MB, Lagrange A, Favier L, Coudert B, Arnould L, Ladoire S, Routy B, Joubert P, Ghiringhelli F

Cancer Cell. 2022 Jan 17;:

Using a convolutional neural network for classification of squamous and non-squamous non-small cell lung cancer based on diagnostic histopathology HES images.

Le Page AL, Ballot E, Truntzer C, Derangère V, Ilie A, Rageot D, Bibeau F, Ghiringhelli F

Sci Rep. 2021 Dec 13;11(1):23912

Utility of exome sequencing in routine care for metastatic colorectal cancer.

D'Agay MG, Galland L, Tharin Z, Truntzer C, Ghiringhelli F

Mol Clin Oncol. 2021 Nov;15(5):229

TCR Clonality and Genomic Instability Signatures as Prognostic Biomarkers in High Grade Serous Ovarian Cancer.

Lecuelle J, Boidot R, Mananet H, Derangère V, Albuisson J, Goussot V, Arnould L, Tharin Z, Ray Coquard I, Ghiringhelli F, Truntzer C, Fumet JD

Cancers (Basel). 2021 Aug 31;13(17):

Does large NGS panel analysed using exome tumour sequencing improve the management of advanced non-small-cell lung cancers?

Niogret J, Dalens L, Truntzer C, Chevrier S, Favier L, Lagrange A, Coudert B, Fraisse C, Foucher P, Zouak A, Westeel V, Goussot V, Dérangère V, Albuisson J, Arnould L, Boidot R, Kaderbhai CG, Ghiringhelli F

Lung Cancer. 2021 Aug 29;161:98-107

Deep learning for colon cancer histopathological images analysis.

Ben Hamida A, Devanne M, Weber J, Truntzer C, Derangère V, Ghiringhelli F, Forestier G, Wemmert C

Comput Biol Med. 2021 Aug 4;136:104730

infection has a detrimental impact on the efficacy of cancer immunotherapies.

Oster P, Vaillant L, Riva E, McMillan B, Begka C, Truntzer C, Richard C, Leblond MM, Messaoudene M, Machremi E, Limagne E, Ghiringhelli F, Routy B, Verdeil G, Velin D

Gut. 2021 Jul 12;:

Splenic Volume as a Surrogate Marker of Immune Checkpoint Inhibitor Efficacy in Metastatic Non Small Cell Lung Cancer.

Galland L, Lecuelle J, Favier L, Fraisse C, Lagrange A, Kaderbhai C, Truntzer C, Ghiringhelli F

Cancers (Basel). 2021 Jun 16;13(12):

Evaluation of tumor immune contexture among intrinsic molecular subtypes helps to predict outcome in early breast cancer.

Klopfenstein Q, Derangère V, Arnould L, Thibaudin M, Limagne E, Ghiringhelli F, Truntzer C, Ladoire S

J Immunother Cancer. 2021 06;9(6):

Follicular helper-T cells restore CD8-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy.

Niogret J, Berger H, Rebe C, Mary R, Ballot E, Truntzer C, Thibaudin M, Derangère V, Hibos C, Hampe L, Rageot D, Accogli T, Joubert P, Routy B, Harker J, Vegran F, Ghiringhelli F, Chalmin F

J Immunother Cancer. 2021 Jun;9(6):

Using Exome Sequencing to Improve Prediction of FOLFIRINOX First Efficacy for Pancreatic Adenocarcinoma.

Lecuelle J, Aarnink A, Tharin Z, Truntzer C, Ghiringhelli F

Cancers (Basel). 2021 Apr 13;13(8):

Seroprevalence of SARS-CoV-2 among the staff and patients of a French cancer centre after first lockdown: The canSEROcov study.

Ladoire S, Goussot V, Redersdorff E, Cueff A, Ballot E, Truntzer C, Ayati S, Bengrine-Lefevre L, Bremaud N, Coudert B, Desmoulins I, Favier L, Fraisse C, Fumet JD, Hanu R, Hennequin A, Hervieu A, Ilie S, Kaderbhai C, Lagrange A, Martin N, Mazilu I, Mayeur D, Palmier R, Simonet-Lamm AL, Vincent J, Zanetta S, Arnould L, Coutant C, Bertaut A, Ghiringhelli F

Eur J Cancer. 2021 Feb 27;148:359-370

Prognostic value of Thyroid Transcription Factor-1 expression in lung adenocarcinoma in patients treated with anti PD-1/PD-L1.

Galland L, Le Page AL, Lecuelle J, Bibeau F, Oulkhouir Y, Derangère V, Truntzer C, Ghiringhelli F

Oncoimmunology. 2021 ;10(1):1957603

Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.

Medjebar S, Truntzer C, Perrichet A, Limagne E, Fumet JD, Richard C, Elkrief A, Routy B, Rébé C, Ghiringhelli F

Oncoimmunology. 2020 Oct 27;9(1):1836766

Tumor Infiltrating Lymphocytes Signature as a New Pan-Cancer Predictive Biomarker of Anti PD-1/PD-L1 Efficacy.

Ballot E, Ladoire S, Routy B, Truntzer C, Ghiringhelli F

Cancers (Basel). 2020 Aug 26;12(9):

Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable a

Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F

BMC Cancer. 2020 Aug 10;20(1):748

Role of pleural and peritoneal metastasis in immune checkpoint inhibitors efficacy patients with non-small cell lung cancer: real-world data from a large cohort in France.

Aarnink A, Fumet JD, Favier L, Truntzer C, Ghiringhelli F

J. Cancer Res. Clin. Oncol.. 2020 May 30;:

Tumour mutational burden as a biomarker for immunotherapy: Current data and emerging concepts.

Fumet JD, Truntzer C, Yarchoan M, Ghiringhelli F

Eur. J. Cancer. 2020 Apr 9;131:40-50

Implementation and use of whole exome sequencing in daily practice for metastatic solid cancer.

Réda M, Richard C, Bertaut A, Niogret J, Collot T, Fumet JD, Blanc J, Truntzer C, Desmoulins I, Ladoire S, Hennequin A, Favier L, Bengrine L, Vincent J, Hervieu A, Dusserre JG, Lepage C, Foucher P, Borg C, Albuisson J, Arnould L, Nambot S, Faivre L, Boidot R, Ghiringhelli F

EBioMedicine. 2020 Jan 7;51:102624

Solid-type adenoid cystic carcinoma of the breast, a distinct molecular entity enriched in NOTCH and CREBBP mutations.

Massé J, Truntzer C, Boidot R, Khalifa E, Pérot G, Velasco V, Mayeur L, Billerey-Larmonier C, Blanchard L, Charitansky H, Soubeyran I, Iggo R, Arnould L, MacGrogan G

Mod. Pathol.. 2019 Dec 19;:

Prognostic value of transcriptomic determination of tumour-infiltrating lymphocytes in localised breast cancer.

Truntzer C, Isambert N, Arnould L, Ladoire S, Ghiringhelli F

Eur. J. Cancer. 2019 Sep 6;120:97-106

Cell lines and immune classification of glioblastoma define patient's prognosis.

Klopfenstein Q, Truntzer C, Vincent J, Ghiringhelli F

Br. J. Cancer. 2019 Mar 22;:

Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.

Limagne E, Richard C, Thibaudin M, Fumet JD, Truntzer C, Lagrange A, Favier L, Coudert B, Ghiringhelli F

Oncoimmunology. 2019 ;8(4):e1564505

Genomic biomarker of checkpoint efficacy, highways for precision medicine in lung cancer.

Ghiringhelli F, Truntzer C

Oncotarget. 2018 Nov 27;9(93):36547-36548

RAS status and neoadjuvant chemotherapy impact CD8+ cells and tumor HLA class I expression in liver metastatic colorectal cancer.

Ledys F, Klopfenstein Q, Truntzer C, Arnould L, Vincent J, Bengrine L, Remark R, Boidot R, Ladoire S, Ghiringhelli F, Derangere V

J Immunother Cancer. 2018 Nov 19;6(1):123

Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy.

Fumet JD, Richard C, Ledys F, Klopfenstein Q, Joubert P, Routy B, Truntzer C, Gagné A, Hamel MA, Guimaraes CF, Coudert B, Arnould L, Favier L, Lagrange A, Ladoire S, Saintigny P, Ortiz-Cuaran S, Perol M, Foucher P, Hofman P, Ilie M, Chevrier S, Boidot R, Derangere V, Ghiringhelli F

Br. J. Cancer. 2018 Oct 15;:

Exome analysis reveals genomic markers associated with better efficacy of nivolumab in lung cancer patients.

Richard C, Fumet JD, Chevrier S, Derangère V, Ledys F, Lagrange A, Favier L, Coudert B, Arnould L, Truntzer C, Boidot R, Ghiringhelli F

Clin. Cancer Res.. 2018 Aug 28;:

Baseline splenic volume as a surrogate marker of FOLFIRINOX efficacy in advanced pancreatic carcinoma.

Aarnink A, Richard C, Truntzer C, Vincent J, Bengrine L, Vienot A, Borg C, Ghiringhelli F

Oncotarget. 2018 May 22;9(39):25617-25629

Solid papillary carcinoma with reverse polarity of the breast harbors specific morphologic, immunohistochemical and molecular profile in comparison with other benign or malignant papillary lesions of the breast: a comparative study of 9 additional cases.

Alsadoun N, MacGrogan G, Truntzer C, Lacroix-Triki M, Bedgedjian I, Koeb MH, El Alam E, Medioni D, Parent M, Wuithier P, Robert I, Boidot R, Arnould L

Mod. Pathol.. 2018 May 21;:

Linear MALDI-ToF simultaneous spectrum deconvolution and baseline removal.

Picaud V, Giovannelli JF, Truntzer C, Charrier JP, Giremus A, Grangeat P, Mercier C

BMC Bioinformatics. 2018 Apr 5;19(1):123

Variance component analysis to assess protein quantification in biomarker discovery. Application to MALDI-TOF mass spectrometry.

Mercier C, Klich A, Truntzer C, Picaud V, Giovannelli JF, Ducoroy P, Grangeat P, Maucort-Boulch D, Roy P

Biom J. 2018 Mar;60(2):262-274

Cholesterol trafficking and raft-like membrane domain composition mediate scavenger receptor class B type 1-dependent lipid sensing in intestinal epithelial cells.

Morel E, Ghezzal S, Lucchi G, Truntzer C, Pais de Barros JP, Simon-Plas F, Demignot S, Mineo C, Shaul PW, Leturque A, Rousset M, Carrière V

Biochim. Biophys. Acta. 2018 02;1863(2):199-211

Bayesian inference for biomarker discovery in proteomics: an analytic solution.

Dridi N, Giremus A, Giovannelli JF, Truntzer C, Hadzagic M, Charrier JP, Gerfault L, Ducoroy P, Lacroix B, Grangeat P, Roy P

EURASIP J Bioinform Syst Biol. 2017 Dec;2017(1):9

Associations between food consumption patterns and saliva composition: Specificities of eating difficulties children.

Morzel M, Truntzer C, Neyraud E, Brignot H, Ducoroy P, Lucchi G, Canlet C, Gaillard S, Nicod F, Nicklaus S, Peretti N, Feron G

Physiol. Behav.. 2017 May;173:116-123

Cholesterol metabolism and glaucoma: Modulation of Muller cell membrane organization by 24S-hydroxycholesterol.

Gambert S, Gabrielle PH, Masson E, Leger-Charnay E, Ferrerro A, Vannier A, Gendrault C, Lachot M, Creuzot-Garcher C, Bron A, Gregoire S, Leclere L, Martine L, Lucchi G, Truntzer C, Pecqueur D, Bretillon L

Chem. Phys. Lipids. 2017 May;:

Peroxisomal ATP-binding cassette transporters form mainly tetramers.

Geillon F, Gondcaille C, Raas Q, Dias AM, Pecqueur D, Truntzer C, Lucchi G, Ducoroy P, Falson P, Savary S, Trompier D

J. Biol. Chem.. 2017 Mar;:

Immune classifications with cytotoxic CD8(+) and Th17 infiltrates are predictors of clinical prognosis in glioblastoma.

Madkouri R, Kaderbhai CG, Bertaut A, Truntzer C, Vincent J, Aubriot-Lorton MH, Farah W, Limagne E, Ladoire S, Boidot R, Derangère V, Ghiringhelli F

Oncoimmunology. 2017 ;6(6):e1321186

Blood baseline neutrophil count predicts bevacizumab efficacy in glioblastoma.

Bertaut A, Truntzer C, Madkouri R, Kaderbhai CG, Derangère V, Vincent J, Chauffert B, Aubriot-Lorton MH, Farah W, Mourier KL, Boidot R, Ghiringhelli F

Oncotarget. 2016 Oct;7(43):70948-70958

Specific enrichment of 2-arachidonoyl-lysophosphatidylcholine in carotid atheroma plaque from type 2 diabetic patients.

Ménégaut L, Masson D, Abello N, Denimal D, Truntzer C, Ducoroy P, Lagrost L, Pais de Barros JP, Athias A, Petit JM, Martin L, Steinmetz E, Kretz B

Atherosclerosis. 2016 Aug;251:339-47

A measure of the impact of CV incompleteness on prediction error estimation with application to PCA and normalization.

Hornung R, Bernau C, Truntzer C, Wilson R, Stadler T, Boulesteix AL

BMC Med Res Methodol. 2015 Nov;15:95

Multi-omics profiling reveals that eating difficulties developed consecutively to artificial nutrition in the neonatal period are associated to specific saliva composition.

Morzel M, Neyraud E, Brignot H, Ducoroy P, Jeannin A, Lucchi G, Truntzer C, Canlet C, Tremblay-Franco M, Hirtz C, Gaillard S, Peretti N, Feron G

J Proteomics. 2015 Jul 29;128:105-112

Towards the identification of two glycoproteins involved in the stomatal deregulation of downy mildew infected grapevine leaves.

Guillier C, Gamm M, Lucchi G, Truntzer C, Pecqueur D, Ducoroy P, Adrian M, Heloir MC

Mol Plant Microbe Interact. 2015 Jun 24.

Genetic diversity and trait genomic prediction in a pea diversity panel.

Burstin J, Salloignon P, Chabert-Martinello M, Magnin-Robert JB, Siol M, Jacquin F, Chauveau A, Pont C, Aubert G, Delaitre C, Truntzer C, Duc G

BMC Genomics. 2015 Feb 21;16(1):105.

Interplays between nitric oxide and reactive oxygen species in cryptogein signalling.

Kulik A, Noirot E, Grandperret V, Bourque S, Fromentin J, Salloignon P, Truntzer C, Dobrowolska G, Simon-Plas F, Wendehenne D

Plant Cell Environ. 2015 Feb;38(2):331-48

Comparison of classification methods that combine clinical data and high-dimensional mass spectrometry data.

Truntzer C, Mostacci E, Jeannin A, Petit JM, Ducoroy P, Cardot H

BMC Bioinformatics. 2014 Nov 29;15:385

Profiling serologic biomarkers in cirrhotic patients via high-throughput Fourier transform infrared spectroscopy: toward a new diagnostic tool of hepatocellular carcinoma.

Zhang X, Thiefin G, Gobinet C, Untereiner V, Taleb I, Bernard-Chabert B, Heurgue A, Truntzer C, Ducoroy P, Hillon P, Sockalingum GD

Transl Res. 2013 Nov;162(5):279-86

Diagnosis of hepatocellular carcinoma in cirrhotic patients: a proof-of-concept study using serum micro-Raman spectroscopy.

Taleb I, Thiefin G, Gobinet C, Untereiner V, Bernard-Chabert B, Heurgue A, Truntzer C, Hillon P, Manfait M, Ducoroy P, Sockalingum GD

Analyst. 2013 Jul 21;138(14):4006-14

Alpha-defensins secreted by dysplastic granulocytes inhibit the differentiation of monocytes in chronic myelomonocytic leukemia.

Droin N, Jacquel A, Hendra JB, Racoeur C, Truntzer C, Pecqueur D, Benikhlef N, Ciudad M, Guery L, Jooste V, Dufour E, Fenaux P, Quesnel B, Kosmider O, Fontenay M, Ducoroy P, Solary E

Blood. 2010 Jan 7;115(1):78-88

Importance of data structure in comparing two dimension reduction methods for classification of microarray gene expression data.

Truntzer C, Mercier C, Esteve J, Gautier C, Roy P

BMC Bioinformatics. 2007 Mar 13;8:90.

Mme TRUNTZER Caroline

Fiche personne

Coordonnées

Territoire

Statut

Affiliation

Équipes/plateformes

Publications

Retrouvez aussi